Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 23 November 2018, 07:14 HKT/SGT
Share:
    

Source: Eisai
Eisai to Present Latest Data on Perampanel at 72nd American Epilepsy Society Annual Meeting

TOKYO, Nov 23, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 72nd American Epilepsy Society Annual Meeting (AES 2018) to be held from November 30 to December 4, 2018 in New Orleans in the United States.

Nineteen poster presentations will be given by Eisai at AES 2018, including reports on the interim analysis results of a Phase III clinical study (Study 311) in pediatric patients aged 4 to less than 12 years as well as a presentation on sustained seizure-free status in the open-label extension phase of a Phase III clinical study (Study 307) in patients 12 years of age and older. Including Investigator Initiated Studies, more than 50 scientific posters on perampanel will be presented at AES 2018.

Perampanel is a first-in-class AED discovered at Eisai's Tsukuba Research Laboratories. It is available in tablet form to be taken once daily, and a new oral suspension formulation has been approved and is being marketed in the United States. A highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation by targeting glutamate activity at AMPA receptors on postsynaptic membranes, it is approved in countries around the world as an adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures, and primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older. Furthermore, perampanel is also indicated for monotherapy and adjunctive use in the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older in the United States.

Eisai considers neurology including epilepsy, a therapeutic area of focus, and strives to deliver perampanel throughout the world in pursuit of our mission to provide "seizure freedom" to a greater number of patients living with epilepsy. Eisai seeks to address the diverse needs of, as well as increasing the benefits provided to, patients with epilepsy and their families.


About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Nov 23, 2018 07:14 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
June 18, 2019 12:32 HKT/SGT
Eisai: Total Synthesis and Nonclinical Study Results of a Novel Anticancer Drug Candidate E7130
June 18, 2019 12:11 HKT/SGT
Eisai to Present Latest Data on Perampanel at 33rd International Epilepsy Congress
May 29, 2019 09:05 HKT/SGT
Eisai to Present Latest Data on Lemborexant including Integrated Analysis of Phase III Clinical Studies at 33rd Annual Sleep Meeting
May 17, 2019 15:34 HKT/SGT
"Science Based Targets (SBT) Initiative" Approves Eisai's Greenhouse Gas Reduction Targets
May 16, 2019 07:37 HKT/SGT
Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting
May 10, 2019 12:34 HKT/SGT
Eisai Enters Into Licensing Agreement With Medac Concerning Anti-Rheumatic Agent Methotrexate Subcutaneous Injection in Japan
May 10, 2019 11:55 HKT/SGT
Eisai: Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401
May 9, 2019 11:33 HKT/SGT
Eisai and Allm Enter Into Capital and Business Alliance Agreement for ICT Healthcare Solutions
May 9, 2019 11:06 HKT/SGT
Eisai Commences Venture Investment Business Aimed at Accelerating Innovation in Drug Creation and Establishment of Ecosystem Platform
May 8, 2019 08:37 HKT/SGT
Eisai and UK Dementia Research Institute Jointly Launch New Post-Doctoral Programme to Accelerate Dementia Research
More news >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: